In today's scenario of global climate change, there is a colossal demand for sustainable
industrial processes and enzymes from thermophiles. Plausibly, thermozymes are an …

Therapeutic advances for neurological disorders are challenging due to limited accessibility
of the human central nervous system and incomplete understanding of disease …

The challenges in making animal models of complex human epilepsy phenotypes with
varied aetiology highlights the need to develop alternative disease models that can address …

Variants in the SCN1A gene are associated with a wide range of disorders including genetic
epilepsy with febrile seizures plus (GEFS+), familial hemiplegic migraine (FHM), and the …

Epilepsy is among the most common neurological disorders, affecting approximately 50
million people worldwide. Importantly, epilepsy is genetically and etiologically …

Background Epilepsy is a common neurological disorder with complex pathogenic
mechanisms, and refractory epilepsy often lacks effective treatments. Gene therapy is a …

Mutations in the SCN1A gene can cause a variety of phenotypes, ranging from mild forms,
such as febrile seizures and generalized epilepsy with febrile seizures plus, to severe, such …

Dravet syndrome (DS) is an intractable form of childhood epilepsy that occurs in infancy.
More than 80% of all patients have a heterozygous abnormality in the SCN1A gene, which …

Knock-in (KI) gene targeting can be employed for a wide range of applications in stem cell
research. However, vectors for KI require multiple complicated processes for construction …

Epilepsy is the most common chronic neurological disease, affecting nearly 1%–2% of the
world's population. Current pharmacological treatment and regimen adjustments are aimed …